Study of MK0677 for the Treatment of Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00074529
First received: December 15, 2003
Last updated: January 30, 2009
Last verified: January 2009
  Purpose

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.


Condition Intervention Phase
Alzheimer's Disease
Drug: MK0677
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Cognitive function over 12 month period; safety and tolerability [ Time Frame: over 12 month period ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog. [ Time Frame: over a 6 month and 12 month period ] [ Designated as safety issue: No ]

Enrollment: 512
Study Start Date: November 2003
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Patients must have probable Alzheimer's disease of mild or moderate severity.
  • A brain scan and laboratory results must be consistent with Alzheimer's disease.
  • The patient must be otherwise medically healthy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00074529

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier: NCT00074529     History of Changes
Other Study ID Numbers: 2006_412, Formally-BG0812AZ, MK0677-030
Study First Received: December 15, 2003
Last Updated: January 30, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on July 20, 2014